Catalyst Funds Management Pty LTD Denali Therapeutics Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 2,000 shares of DNLI stock, worth $46,580. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000Holding current value
$46,580% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$311 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$307 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$260 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$250 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$184 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.12B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...